NEW OPTION FOR MANAGEMENT OF HIGH-RISK SOFT TISSUE SARCOMA OF THE LIMB International, multi-centre sarcoma trial shows benefits of integrating immunotherapy with radiotherapy and surgery
The Australia and New Zealand Sarcoma Association (ANZSA) is the peak body for the sarcoma community. ANZSA aims to improve outcomes for sarcoma patients through research, education and awareness of sarcomas and related tumours.
ANZSA fosters effective collaborations across multi-disciplinary teams (MDT), which comprise of specialist health professionals (including pathologists, radiologists, surgeons, radiation oncologists, medical oncologists and paediatric oncologists) working together to discuss sarcoma and related tumours cases, and how to best manage treatment and care.
Professor Angela Hong MBBS, MMed, PhD, FRANZCR is the co-Chair of ANZSA’s Scientific Advisory Committee and a Professor at Sydney Medical School of the University of Sydney. She is a radiation oncologist and has been a member of the Multidisciplinary Bone and Soft Tissue Tumour Clinic at Royal Prince Alfred Hospital/Chris O’Brien Lifehouse for the past 15 years.
As a clinician scientist, her research focuses on developing innovative radiation therapy technique and combination treatments to improve the outcome for patients with sarcoma.
Professor Hong spoke to Australian Health Journal about sarcoma and a recently concluded international, multicentre trial, that could lead to a new potential option for patients grappling with high-risk sarcoma of the limb.
Soft tissue sarcoma, a rare aggressive cancer originating in connective tissues, can affect both children and adults. It is particularly challenging to conduct clinical trials due to its rarity, However a recently concluded international collaborative Phase II clinical trial SARC032 has shown groundbreaking findings into the advantages of Immunotherapy for patients with high-risk soft tissue sarcoma of the limb
The trial was led by the Sarcoma Alliance Research Collaboration (SARC) in the United States and the Australia and New Zealand Sarcoma Association (ANZSA) in Australia. The Australian participating sites in the trial were Peter MacCallum Cancer Centre, Chris O’Brien Lifehouse and Princess Alexandra Hospital.
SARC032 is the first completed randomised clinical trial of its kind and has demonstrated compelling evidence to integrate immunotherapy, with the standard treatment regimen of radiotherapy and surgery for patients with grade 2 or 3, stage III soft tissue sarcoma of the limb.
Professor Angela Hong, Australia’s Principal Investigator for the trial, believes these results will be beneficial for patients for this specific stage of sarcoma.
“This is a significant milestone. The integration of immunotherapy into standard treatment protocols heralds a new era in sarcoma management, offering patients and clinicians a potent tool in the battle against this formidable disease.”
-
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
-
The Case for Embedded Pharmacy in Residential Aged Care
Embedded pharmacy in residential aged care has been successful in South Australia at the Tanunda Lutheran Home in the Barossa Valley. Julian Soriano talks about his pharmacy role in medication management and medication safety to deliver the best clinical care for residents.
In this segment, Julian talks about the traditional pharmacy model serving residential aged care and the limitations of the imprest process for dispensing medication. Soon into the project he saw the collaboration required with GPs and onsite nurses in dispensing medication for residents in end-of-life or palliative care. Julian sees the imprest process unable to support end-of-life residents, even being able to check the availability of medication.
But what most may not be aware of, is his rapid growth since starting the business in 2013 having just been in health care a few years earlier. Being part of a 2nd generation health care family, Shawn learnt from his father on site and at trade show visits overseas. Prior to HPA, he spent 2 years working in fit-outs of operating theatres, neo-natal and general population ICU, throughout being more fascinated with what he saw. -
Care workforce challenges
In a wide ranging report looking at the carer needs across Australia, PwC Australia published Reimagine Care Workforce Solutions in October 2022.
Australian Health Journal spoke with Kerryn Dillon, Director Ageing and Reablement and Health Workforce at PwC Australia about the community care sectors of aged care, disability care and childcare the report covers.
